Skip to main content
Premium Trial:

Request an Annual Quote

Hiroaki Tanaka, Robert Abarbanel, Michael Bailey, Kaley Parkinson, John Hanlon

Premium

Among other management changes, Paris-based Genset has promoted Hiroaki Tanaka as VP of bioinformatics. Tanaka, who has led Genset’s bioinformatics group since 1998, will replace CIO and CTO Robert Abarbanel and will oversee approximately 70 employees engaged in R&D.

 

Michael Bailey, formerly CIO of PeoplePC, has been tapped as Berkeley, Calif.-based Sygen International’s new CIO. He will be responsible for the company’s global IT strategy and organization.

 

Life science IT newcomer Visualize of Pheonix, Ariz., has hired Kaley Parkinson as CFO. Before joining Visualize, Parkinson was CEO of clickfind.com, which provided e-commerce tools to the pharmaceutical industry. Visualize recently acquired the software assets of Genomica and plans to relaunch its products in the next few months.

 

Princeton, NJ-based Pharmacopeia has hired John Hanlon as executive VP and CFO. Hanlon was formerly CFO of MDL Information Systems, and most recently served as CFO of Digital Courier Technologies, an e-payment service provider.

Filed under

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.